摘要
This nationwide surveillance of clinically important bacteria from the intensive care units (ICUs) of major teaching hospitals throughout Taiwan investigated the susceptibilities to doripenem and other comparator carbapenems from September through November 2005. Minimum inhibitory concentrations (MICs) were determined for 1,311 clinical isolates using the broth microdilution method according to Clinical and Laboratory Standards Institute (CLSI) 2005 guidelines. Doripenem showed similar (within four-fold difference of MICs) in vitro activity to meropenem for Enterobacteriaceae and probably comparable activity to meropenem against important nosocomial non-fermentative Gram-negative bacilli (NFGNBs), including Pseudomonas aeruginosa, Acinetobacter baumannii and Burkholderia cepacia. Among the four carbapenems analysed, doripenem and meropenem exhibited better in vitro activity than imipenem or ertapenem against extended-spectrum β-lactamase (ESBL)-producing Klebsiella pneumoniae and Escherichia coli isolates. However, the meropenem MIC 90 against ESBL-producing K. pneumoniae isolates was 2 μg/ml. Besides, doripenem with the MIC90 of 0.5 μg/ml to Streptococcus pneumoniae possibly suggested its potential therapeutic effect regarding community-acquired pneumonia. Because of the heavy resistance burden in Taiwan, closely monitoring the evolutionary trend of carbapenem susceptibilities against clinically important pathogens is crucial in the future.
| 原文 | 英語 |
|---|---|
| 頁（從 - 到） | 471-475 |
| 頁數 | 5 |
| 期刊 | European Journal of Clinical Microbiology and Infectious Diseases |
| 卷 | 29 |
| 發行號 | 4 |
| DOIs | |
| 出版狀態 | 已發佈 - 四月 2010 |
| 對外發佈 | Yes |
指紋
ASJC Scopus subject areas
- Microbiology (medical)
- Infectious Diseases
引用此文
In vitro activities of doripenem and other carbapenems against clinically important bacteria isolated in intensive care units : Nationwide data from the SMART Programme. / Jean, S. S.; Hsueh, P. R.; Lee, W. S.; Chang, H. T.; Chou, M. Y.; Chen, I. S.; Wang, J. H.; Lin, C. F.; Shyr, J. M.; Ko, W. C.; Wu, J. J.; Liu, Y. C.; Huang, W. K.; Teng, L. J.; Liu, C. Y.
於: European Journal of Clinical Microbiology and Infectious Diseases, 卷 29, 編號 4, 04.2010, p. 471-475.研究成果: 雜誌貢獻 › 文章
}
TY - JOUR
T1 - In vitro activities of doripenem and other carbapenems against clinically important bacteria isolated in intensive care units
T2 - Nationwide data from the SMART Programme
AU - Jean, S. S.
AU - Hsueh, P. R.
AU - Lee, W. S.
AU - Chang, H. T.
AU - Chou, M. Y.
AU - Chen, I. S.
AU - Wang, J. H.
AU - Lin, C. F.
AU - Shyr, J. M.
AU - Ko, W. C.
AU - Wu, J. J.
AU - Liu, Y. C.
AU - Huang, W. K.
AU - Teng, L. J.
AU - Liu, C. Y.
PY - 2010/4
Y1 - 2010/4
N2 - This nationwide surveillance of clinically important bacteria from the intensive care units (ICUs) of major teaching hospitals throughout Taiwan investigated the susceptibilities to doripenem and other comparator carbapenems from September through November 2005. Minimum inhibitory concentrations (MICs) were determined for 1,311 clinical isolates using the broth microdilution method according to Clinical and Laboratory Standards Institute (CLSI) 2005 guidelines. Doripenem showed similar (within four-fold difference of MICs) in vitro activity to meropenem for Enterobacteriaceae and probably comparable activity to meropenem against important nosocomial non-fermentative Gram-negative bacilli (NFGNBs), including Pseudomonas aeruginosa, Acinetobacter baumannii and Burkholderia cepacia. Among the four carbapenems analysed, doripenem and meropenem exhibited better in vitro activity than imipenem or ertapenem against extended-spectrum β-lactamase (ESBL)-producing Klebsiella pneumoniae and Escherichia coli isolates. However, the meropenem MIC 90 against ESBL-producing K. pneumoniae isolates was 2 μg/ml. Besides, doripenem with the MIC90 of 0.5 μg/ml to Streptococcus pneumoniae possibly suggested its potential therapeutic effect regarding community-acquired pneumonia. Because of the heavy resistance burden in Taiwan, closely monitoring the evolutionary trend of carbapenem susceptibilities against clinically important pathogens is crucial in the future.
AB - This nationwide surveillance of clinically important bacteria from the intensive care units (ICUs) of major teaching hospitals throughout Taiwan investigated the susceptibilities to doripenem and other comparator carbapenems from September through November 2005. Minimum inhibitory concentrations (MICs) were determined for 1,311 clinical isolates using the broth microdilution method according to Clinical and Laboratory Standards Institute (CLSI) 2005 guidelines. Doripenem showed similar (within four-fold difference of MICs) in vitro activity to meropenem for Enterobacteriaceae and probably comparable activity to meropenem against important nosocomial non-fermentative Gram-negative bacilli (NFGNBs), including Pseudomonas aeruginosa, Acinetobacter baumannii and Burkholderia cepacia. Among the four carbapenems analysed, doripenem and meropenem exhibited better in vitro activity than imipenem or ertapenem against extended-spectrum β-lactamase (ESBL)-producing Klebsiella pneumoniae and Escherichia coli isolates. However, the meropenem MIC 90 against ESBL-producing K. pneumoniae isolates was 2 μg/ml. Besides, doripenem with the MIC90 of 0.5 μg/ml to Streptococcus pneumoniae possibly suggested its potential therapeutic effect regarding community-acquired pneumonia. Because of the heavy resistance burden in Taiwan, closely monitoring the evolutionary trend of carbapenem susceptibilities against clinically important pathogens is crucial in the future.
UR - http://www.scopus.com/inward/record.url?scp=77952097095&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77952097095&partnerID=8YFLogxK
U2 - 10.1007/s10096-009-0866-6
DO - 10.1007/s10096-009-0866-6
M3 - Article
C2 - 20108018
AN - SCOPUS:77952097095
VL - 29
SP - 471
EP - 475
JO - European Journal of Clinical Microbiology and Infectious Diseases
JF - European Journal of Clinical Microbiology and Infectious Diseases
SN - 0934-9723
IS - 4
ER -